UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the three months ended March 31, 2023
Commission
File No. 001-41010
MAINZ
BIOMED N.V.
(Translation
of registrant’s name into English)
Robert
Koch Strasse 50
55129 Mainz
Germany
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) ☐
Other
Events
On
May 16, 2023, Mainz Biomed N.V. made available its Management’s Discussion and Analysis of Financial Condition and Results of Operations
for the three months ended March 31, 2023. A copy of the report is attached hereto as Exhibit 99.1.
On
May 16, 2023, Mainz Biomed N.V. made available its Financial Statements for the three months ended March 31, 2023. A copy of the report
is attached hereto as Exhibit 99.2.
Furnished
as Exhibit 99.3 to this Report on Form 6-K is a press release of Mainz Biomed N.V. (the “Company”) dated May 16, 2023, announcing
the Company’s results for the three months ended March 31, 2023.
This current report on Form 6-K and exhibits 99.1 and 99.2 hereto are hereby
incorporated by reference into the Company’s Registration Statement
on Form F-3 (File No. 333-269091).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
May 16, 2023 |
By: |
/s/
William J. Caragol |
| |
Name: |
William
J. Caragol |
| |
Title |
Chief
Financial Officer |
2
